NASDAQ:NK - Nantkwest News Headlines

$1.27
+0.02 (+1.60 %)
(As of 07/24/2019 04:26 AM ET)
Today's Range
$1.20
Now: $1.27
$1.33
50-Day Range
$1.00
MA: $1.10
$1.31
52-Week Range
$0.93
Now: $1.27
$4.23
Volume430,100 shs
Average Volume427,390 shs
Market Capitalization$125.32 million
P/E RatioN/A
Dividend YieldN/A
Beta2.31

Headlines

Nantkwest (NASDAQ NK) News Headlines

Source:
DateHeadline
-$0.25 Earnings Per Share Expected for Nantkwest Inc (NASDAQ:NK) This Quarter-$0.25 Earnings Per Share Expected for Nantkwest Inc (NASDAQ:NK) This Quarter
www.americanbankingnews.com - July 16 at 2:23 PM
NantKwest: Continues To Sell Off Despite The Clinical Progress - Seeking AlphaNantKwest: Continues To Sell Off Despite The Clinical Progress - Seeking Alpha
seekingalpha.com - July 12 at 9:27 AM
Did Changing Sentiment Drive NantKwest's (NASDAQ:NK) Share Price Down A Painful 82%?Did Changing Sentiment Drive NantKwest's (NASDAQ:NK) Share Price Down A Painful 82%?
finance.yahoo.com - July 11 at 9:19 AM
Nantkwest Inc (NASDAQ:NK) Sees Large Growth in Short InterestNantkwest Inc (NASDAQ:NK) Sees Large Growth in Short Interest
www.americanbankingnews.com - June 29 at 10:19 PM
NantKwest Launches First-in-class, First-in-human Phase I Clinical Trial With a Targeted PD-L1 t-haNK Cell Therapy in Patients With Solid Tumors - Yahoo FinanceNantKwest Launches First-in-class, First-in-human Phase I Clinical Trial With a Targeted PD-L1 t-haNK Cell Therapy in Patients With Solid Tumors - Yahoo Finance
finance.yahoo.com - June 25 at 10:21 AM
Cheryl Cohen Appointed to NantKwest’s Board of Directors - Yahoo FinanceCheryl Cohen Appointed to NantKwest’s Board of Directors - Yahoo Finance
finance.yahoo.com - June 6 at 5:53 PM
Cheryl Cohen Appointed to NantKwest’s Board of DirectorsCheryl Cohen Appointed to NantKwest’s Board of Directors
finance.yahoo.com - June 6 at 5:53 PM
NantKwest (NK) Announces Updated Clinical Results for Nanatinostat (VRx-3996) - StreetInsider.comNantKwest (NK) Announces Updated Clinical Results for Nanatinostat (VRx-3996) - StreetInsider.com
www.streetinsider.com - June 6 at 9:32 AM
NantKwest Announces Updated Clinical Results for Nanatinostat (VRx-3996), a Novel HDAC Inhibitor Being Developed in Partnership with Viracta Therapeutics - Yahoo FinanceNantKwest Announces Updated Clinical Results for Nanatinostat (VRx-3996), a Novel HDAC Inhibitor Being Developed in Partnership with Viracta Therapeutics - Yahoo Finance
finance.yahoo.com - June 5 at 6:03 PM
NantKwest Announces Durable Complete Responses in Multiple Advanced-Stage Solid Tumor Cancers Following Off-the-Shelf NK Cell Therapy in First 35 Patients - Yahoo FinanceNantKwest Announces Durable Complete Responses in Multiple Advanced-Stage Solid Tumor Cancers Following Off-the-Shelf NK Cell Therapy in First 35 Patients - Yahoo Finance
finance.yahoo.com - June 4 at 9:35 AM
NantKwest Launches First-in-Human Targeted NK Phase I Clinical Trial of CD19 T-haNK Cell Therapy in Lymphoma Patients - Yahoo FinanceNantKwest Launches First-in-Human Targeted NK Phase I Clinical Trial of CD19 T-haNK Cell Therapy in Lymphoma Patients - Yahoo Finance
finance.yahoo.com - June 4 at 9:35 AM
NantKwest Announces Updated Clinical Results for Nanatinostat (VRx-3996), a Novel HDAC Inhibitor Being Developed in Partnership with Viracta TherapeuticsNantKwest Announces Updated Clinical Results for Nanatinostat (VRx-3996), a Novel HDAC Inhibitor Being Developed in Partnership with Viracta Therapeutics
finance.yahoo.com - June 4 at 9:35 AM
NantKwest Announces Durable Complete Responses in Multiple Advanced-Stage Solid Tumor Cancers Following Off-the-Shelf NK Cell Therapy in First 35 PatientsNantKwest Announces Durable Complete Responses in Multiple Advanced-Stage Solid Tumor Cancers Following Off-the-Shelf NK Cell Therapy in First 35 Patients
finance.yahoo.com - June 4 at 9:35 AM
NantKwest Launches First-in-Human Targeted NK Phase I Clinical Trial of CD19 T-haNK Cell Therapy in Lymphoma PatientsNantKwest Launches First-in-Human Targeted NK Phase I Clinical Trial of CD19 T-haNK Cell Therapy in Lymphoma Patients
finance.yahoo.com - June 3 at 5:53 PM
NantKwest to Present and Provide Update at Upcoming Jefferies 2019 Annual Healthcare Conference - Yahoo FinanceNantKwest to Present and Provide Update at Upcoming Jefferies 2019 Annual Healthcare Conference - Yahoo Finance
finance.yahoo.com - June 3 at 9:26 AM
NantKwest, NantCell and NantOmics to Provide Updated Preclinical and Clinical Data in Four Abstracts at Part of the American Society of Clinical Oncology Annual Meeting - Yahoo FinanceNantKwest, NantCell and NantOmics to Provide Updated Preclinical and Clinical Data in Four Abstracts at Part of the American Society of Clinical Oncology Annual Meeting - Yahoo Finance
finance.yahoo.com - May 31 at 9:32 AM
NantKwest, NantCell and NantOmics to Provide Updated Preclinical and Clinical Data in Four Abstracts at Part of the American Society of Clinical Oncology Annual MeetingNantKwest, NantCell and NantOmics to Provide Updated Preclinical and Clinical Data in Four Abstracts at Part of the American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 31 at 9:32 AM
What Kind Of Investor Owns Most Of NantKwest, Inc. (NASDAQ:NK)? - Yahoo FinanceWhat Kind Of Investor Owns Most Of NantKwest, Inc. (NASDAQ:NK)? - Yahoo Finance
finance.yahoo.com - May 23 at 6:26 PM
What Kind Of Investor Owns Most Of NantKwest, Inc. (NASDAQ:NK)?What Kind Of Investor Owns Most Of NantKwest, Inc. (NASDAQ:NK)?
finance.yahoo.com - May 23 at 6:26 PM
Brink Biologics Announces Research License Agreement with Worcester Polytechnic Institute for Use of NantKwest’s NK-92® Cells - Yahoo FinanceBrink Biologics Announces Research License Agreement with Worcester Polytechnic Institute for Use of NantKwest’s NK-92® Cells - Yahoo Finance
finance.yahoo.com - May 1 at 9:17 AM
Brink Biologics Announces Research License Agreement with Worcester Polytechnic Institute for Use of NantKwest’s NK-92® CellsBrink Biologics Announces Research License Agreement with Worcester Polytechnic Institute for Use of NantKwest’s NK-92® Cells
finance.yahoo.com - May 1 at 9:17 AM
Market Trends Toward New Normal in WageWorks, Maxwell Technologies, Valeritas, NantKwest, Nightstar Therapeutics PLC Sponsored ADR, and Aspen Group — Emerging Consolidated Expectations, Analyst Ratings - GlobeNewswireMarket Trends Toward New Normal in WageWorks, Maxwell Technologies, Valeritas, NantKwest, Nightstar Therapeutics PLC Sponsored ADR, and Aspen Group — Emerging Consolidated Expectations, Analyst Ratings - GlobeNewswire
www.globenewswire.com - April 17 at 9:53 AM
NantKwest: Still Going For A Cancer Moonshot - Seeking AlphaNantKwest: Still Going For A Cancer Moonshot - Seeking Alpha
seekingalpha.com - April 10 at 6:44 PM
NantKwest Announces New haNK Natural Killer Cell Patent Issuance Further Expanding Intellectual Property EstateNantKwest Announces New haNK Natural Killer Cell Patent Issuance Further Expanding Intellectual Property Estate
finance.yahoo.com - April 1 at 6:34 PM
Will NantKwest Continue to Surge Higher? - NasdaqWill NantKwest Continue to Surge Higher? - Nasdaq
www.nasdaq.com - April 1 at 9:56 AM
Will NantKwest Continue to Surge Higher?Will NantKwest Continue to Surge Higher?
finance.yahoo.com - April 1 at 9:56 AM
NantKwest up 30% on $39M Soon-Shiong investment - Seeking AlphaNantKwest up 30% on $39M Soon-Shiong investment - Seeking Alpha
seekingalpha.com - March 26 at 9:41 AM
NantKwest Chairman & CEO Dr. Patrick Soon-Shiong Exercises $39 Million in Warrants and Options in Support of NKs Natural Killer Cell Strategic Vision Beyond Check Point Immunotherapy - Business WireNantKwest Chairman & CEO Dr. Patrick Soon-Shiong Exercises $39 Million in Warrants and Options in Support of NK's Natural Killer Cell Strategic Vision Beyond Check Point Immunotherapy - Business Wire
www.businesswire.com - March 25 at 6:24 PM
NantKwest Chairman & CEO Dr. Patrick Soon-Shiong Exercises $39 Million in Warrants and Options in Support of NK’s Natural Killer Cell Strategic Vision Beyond Check Point ImmunotherapyNantKwest Chairman & CEO Dr. Patrick Soon-Shiong Exercises $39 Million in Warrants and Options in Support of NK’s Natural Killer Cell Strategic Vision Beyond Check Point Immunotherapy
finance.yahoo.com - March 25 at 6:23 PM
NantKwest, Inc. Estimate MomentumNantKwest, Inc. Estimate Momentum
www.nasdaq.com - March 18 at 6:36 PM
NantKwest Chairman & CEO Dr. Patrick Soon-Shiong to Present Vision for Next Generation Natural Killer Cell Therapies During Keynote Address at Innate Killer SummitNantKwest Chairman & CEO Dr. Patrick Soon-Shiong to Present Vision for Next Generation Natural Killer Cell Therapies During Keynote Address at Innate Killer Summit
finance.yahoo.com - March 18 at 9:16 AM
NantKwest Signs Worldwide License Agreement with ProMab Biotechnologies to Exclusively Develop Select Next Generation Targeted Natural Killer Cell Therapeutics - Business WireNantKwest Signs Worldwide License Agreement with ProMab Biotechnologies to Exclusively Develop Select Next Generation Targeted Natural Killer Cell Therapeutics - Business Wire
www.businesswire.com - March 4 at 10:40 AM
NantKwest Signs Worldwide License Agreement with ProMab Biotechnologies to Exclusively Develop Select Next Generation Targeted Natural Killer Cell TherapeuticsNantKwest Signs Worldwide License Agreement with ProMab Biotechnologies to Exclusively Develop Select Next Generation Targeted Natural Killer Cell Therapeutics
finance.yahoo.com - March 4 at 10:40 AM
Our Take On NantKwest, Inc.’s (NASDAQ:NK) CEO SalaryOur Take On NantKwest, Inc.’s (NASDAQ:NK) CEO Salary
finance.yahoo.com - February 25 at 6:08 PM
Is the Options Market Predicting a Spike in NantKwest (NK) Stock?Is the Options Market Predicting a Spike in NantKwest (NK) Stock?
www.zacks.com - January 10 at 9:53 AM
NantKwest (NK) Reports Launch of Merkel Cell Carcinoma Phase II Trial - StreetInsider.comNantKwest (NK) Reports Launch of Merkel Cell Carcinoma Phase II Trial - StreetInsider.com
www.streetinsider.com - January 9 at 5:56 PM
NantKwest launches mid-stage study of triplet therapy for rare skin cancerNantKwest launches mid-stage study of triplet therapy for rare skin cancer
seekingalpha.com - January 9 at 9:38 AM
NantKwest Announces Launch of Merkel Cell Carcinoma Phase II Trial Deploying Novel Triple Combination of off-the-Shelf Natural Killer haNKⓇ Cell Therapy with Superagonist IL-15 Cytokine Therapy and PD-L1 Checkpoint Inhibitor TherapyNantKwest Announces Launch of Merkel Cell Carcinoma Phase II Trial Deploying Novel Triple Combination of off-the-Shelf Natural Killer haNKⓇ Cell Therapy with Superagonist IL-15 Cytokine Therapy and PD-L1 Checkpoint Inhibitor Therapy
finance.yahoo.com - January 9 at 9:38 AM
NantKwest to Host 4th Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical ProgramsNantKwest to Host 4th Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs
finance.yahoo.com - January 5 at 9:25 AM
Have Insiders Been Selling NantKwest, Inc. (NASDAQ:NK) Shares?Have Insiders Been Selling NantKwest, Inc. (NASDAQ:NK) Shares?
finance.yahoo.com - December 25 at 4:32 PM
Is Nantkwest Inc (NK) Going to Burn These Hedge Funds?Is Nantkwest Inc (NK) Going to Burn These Hedge Funds?
finance.yahoo.com - December 18 at 4:46 PM
NantKwest to Present Updated Preclinical Data at the 60th Annual Meeting of the American Society of HematologyNantKwest to Present Updated Preclinical Data at the 60th Annual Meeting of the American Society of Hematology
finance.yahoo.com - December 3 at 4:31 PM
NantKwest Zeroes in on Natural Killer Cells, Posts Killer Stock PriceNantKwest Zeroes in on Natural Killer Cells, Posts Killer Stock Price
www.baystreet.ca - November 8 at 4:45 PM
Healthcare Stocks are Gaining Ground in Technology Niche: Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Inovalon Holdings, NantKwest Inc.Healthcare Stocks are Gaining Ground in Technology Niche: Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Inovalon Holdings, NantKwest Inc.
finance.yahoo.com - November 8 at 4:45 PM
Here's Why NantKwest Skyrocketed 26.4% TodayHere's Why NantKwest Skyrocketed 26.4% Today
finance.yahoo.com - November 8 at 4:45 PM
NantKwest Announces Promising First in Human Clinical Results of 300 Doses Of CD16 Targeted, Off-The-Shelf Cryopreserved Natural Killer Cells (haNK) in a Novel Cancer Memory ...NantKwest Announces Promising First in Human Clinical Results of 300 Doses Of CD16 Targeted, Off-The-Shelf Cryopreserved Natural Killer Cells (haNK) in a Novel Cancer Memory ...
www.businesswire.com - November 8 at 9:23 AM
NantKwest up 24% premarket on encouraging cancer memory vaccine dataNantKwest up 24% premarket on encouraging cancer memory vaccine data
seekingalpha.com - November 8 at 9:23 AM
NantKwest Announces Promising First in Human Clinical Results of 300 Doses Of CD16 Targeted, Off-The-Shelf Cryopreserved Natural Killer Cells (haNK) in a Novel Cancer Memory Vaccine ImmunotherapyNantKwest Announces Promising First in Human Clinical Results of 300 Doses Of CD16 Targeted, Off-The-Shelf Cryopreserved Natural Killer Cells (haNK) in a Novel Cancer Memory Vaccine Immunotherapy
finance.yahoo.com - November 8 at 9:23 AM
NantKwest Announces Multiple Presentations at the 2018 Society for Immunotherapy of Cancer ConferenceNantKwest Announces Multiple Presentations at the 2018 Society for Immunotherapy of Cancer Conference
finance.yahoo.com - November 6 at 9:21 AM
Analysts Estimate NantKwest (NK) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate NantKwest (NK) to Report a Decline in Earnings: What to Look Out for
www.zacks.com - October 31 at 9:30 AM
This page was last updated on 7/24/2019 by MarketBeat.com Staff

Featured Article: Stock Split

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel